CENTESSA PHARMACEUTICALS PLC - AMERICAN DEPOSITARY

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

22 Apr 2024 04:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

28 Mar 2024 13:28:47 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference

22 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

09 Feb 2024 04:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

22 Jan 2024 05:00:01 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference

13 Dec 2023 05:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia

10 Dec 2023 09:05:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023

13 Nov 2023 13:05:10 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting

02 Nov 2023 06:09:52 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors

31 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

30 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

25 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Additions to Senior Leadership Team

03 Oct 2023 05:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

31 Aug 2023 05:00:00 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress

23 Aug 2023 14:08:51 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023

14 Aug 2023 04:00:30 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

10 Jul 2023 05:00:04 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

24 May 2023 05:00:09 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B

22 May 2023 04:00:21 By Nasdaq GlobeNewswire

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

12 May 2023 04:00:06 By Nasdaq GlobeNewswire